Orexigen Therapeutics IncMost RecentCompany & Industry OverviewsHow Much Potential Does Saxenda Hold for Novo?Saxenda, a glucagon-like peptide-1 (or GLP-1) analog therapy, holds 31% market share for branded anti-obesity drugs.
Company & Industry OverviewsHow Much Potential Does Saxenda Hold for Novo?Saxenda, a glucagon-like peptide-1 (or GLP-1) analog therapy, holds 31% market share for branded anti-obesity drugs.
